CareDx (CDNA) Stock Forecast & Price Target

CareDx is well positioned for a positive rerating because the final transplant LCD removed a major reimbursement overhang, affirmed kidney, heart, and lung surveillance coverage above current utilization, and preserved the HeartCare bundle and for-cause testing. Its core transplant business is still growing strongly, with Q2’26 revenue of $132M (+52% Y/Y), core test revenue of $100M (+61% Y/Y), volume of 58k (+17% Y/Y), and a raised 2026 revenue guide of $490M-$500M alongside adjusted EBITDA guidance of $66M-$78M. Management also has a credible second growth engine through Naveris and the planned AlloHeme launch, while improved revenue cycle management, stronger ASPs, and a simplified, higher-margin portfolio support upside to earnings power and valuation.

CareDx is exposed to heavy concentration risk because its financial results depend largely on AlloSure Kidney and AlloMap Heart, so any slowdown in reimbursement or demand can quickly pressure revenue. Its growth strategy also hinges on commercializing new diagnostic solutions, but that process requires substantial R&D, clinical validation, approvals, and clinician adoption, all of which can take years and may be disrupted by rapid technology changes. In addition, transplant centers and administrators may resist switching from historical practices, while the recent Naveris acquisition adds integration risk and could distract from execution.